
C/CAN 2025: City Cancer Challenge

C/CAN 2025

Submitted as part of Access Accelerated

Contents

Program Description	4
Program Overview	5
Program Strategies & Activities	8
Companies, Partners & Stakeholders	9
Local Context, Equity & Sustainability	12
Additional Program Information	15
Resources	15
Program Indicators	16
List of indicator data	17
Reduction in premature cancer mortality by 2030	19
Delivery of quality, equitable and sustainable cancer solutions in C/Can 2025 cities - Access	21
Delivery of quality, equitable and sustainable cancer solutions in C/Can 2025 cities - Quality	23
Total population covered	25
Development and strengthening of cancer policies, protocols, and processes	26
Healthcare professionals supported with technical assistance	27
Technical experts providing technical assistance in cancer treatment and care	28
Development of tools, guidance and protocols for cancer treatment and care	29
Number of investment cases and/or business models for project plans finalized and approved	30
Cities collaborating to improve cancer treatment and care	31

Contents

Evidence used to support development of cancer treatment and care solutions	32
Cities engaged in the City Cancer Challenge	33
Percentage of health facilities involved in identifying needs in cancer treatment and care	34
Participation of healthcare professionals in identifying needs in cancer treatment and care	35
Participation of patients in identifying needs in cancer treatment and care	36
Needs assessment completed in cities	37
Technical assistance in cancer treatment and care provided	38
City development of project implementation plans	39
Technical support provided to facilitate sustainable financing of cancer treatment and care	40
Technical experts contributing to technical support on sustainable financing for cancer treatment and care	42
Appendix	42

Program Description

Program Overview

1 Program Name

City Cancer Challenge (C/Can)

2 Diseases program aims to address

- Cancer (Breast, Cervical, Childhood, Colorectal, General, Hematological, Leukemia, Liver)

3 Beneficiary population

- Age groups: All ages
- Genders: All genders
- Special populations: People with low income, Urban populations

4 Countries

- Colombia
- Myanmar
- Paraguay
- Ghana

5 Program start date

January 17, 2017

6 Anticipated program completion date

Completion date not specified

7 Contact person

Jade Chakowa (chakowa@citycancerchallenge.org)

8 Program summary

City Cancer Challenge Foundation (C/Can) supports cities around the world as they work to improve access to equitable, quality cancer care.

C/Can leads a city-based partnership initiative that aims to improve access to quality cancer care in cities around the world by transforming the way stakeholders from the public and private sectors collectively design, plan, and implement cancer solutions.

The approach is built on the core principle that cities can drive impact at national level by crafting data-driven solutions with the support of a network of global, regional, and local partners that reflect an understanding of the unique local context.

C/Can was launched by the Union for International Cancer Control (UICC) at the 2017 World Economic Forum Annual Meeting in Davos. It was established as a standalone Swiss foundation in January 2019.

There are 18.1 million new cancer cases and more than 9.6 million cancer deaths worldwide each year, and these numbers are increasing drastically. With 54% of the world's population living in cities, we believe cities are uniquely positioned to drive sustainable innovation in the delivery of cancer care—and health services in general—to large populations.

Despite recent improvements in cancer care worldwide, access to surgery, radiotherapy, and essential oncology medicines remains an enormous challenge in low- and middle-income countries (LMICs). These issues are compounded by a lack of human resources specialized in cancer care across all regions and income settings.

To address this global challenge, C/Can has developed a “City Engagement Process” that outlines support for participating cities over a two-year period, during which they identify, plan, and implement solutions to close major gaps in quality cancer care—from diagnosis to treatment to palliative and supportive care.

While cities take the lead in developing cancer treatment solutions, they work closely with C/Can's multi-sector community of global and local partners, who provide technical assistance through each phase of the initiative. C/Can recognizes that each city is unique in its social, economic, and environmental development, which means there is no one-size-fits-all city cancer treatment solution. By taking a health systems approach, cities can reduce inequities in access to quality cancer care and improve the health and wellbeing of their citizens.

Cities engaged in C/Can are supported over two/three years to go through a 6 step engagement process to build cancer solutions from the ground up. The City Engagement Process (CEP) is C/Can's framework for assessing, planning, implementing, monitoring, evaluating and adapting cancer care solutions to the local context. Through this systematic process, C/Can cities undertake a 2 to 3 year process that supports cities to engage the right stakeholders, do a comprehensive needs assessment, identify priorities in cancer care and develop solutions to address those priorities.

Program Overview

8 Program summary, cont.

Critical to C/Can achieving its mission is learning how to best work with cities to improve access to quality cancer treatment and care, particularly in low- and middle-income countries (LMICs) where the need is greatest. To this end, activities began in 2017 with four Key Learning Cities: Asunción in Paraguay, Cali in Colombia, Kumasi in Ghana, and Yangon in Myanmar. These cities were selected based upon a rigorous set of criteria, including their potential to provide insights on how the international community, local civil society, and public and private sector can best work together to implement the shared ambitions of the city. Since the beginning of 2018, the initiative has been scaling-up support to a wide network of 'Challenge Cities' that have a population greater than 1 million, in every region.

C/Can is mobilising and engaging a truly multisectoral group of stakeholders, who provide expertise, in-kind and financial support during all phases of the initiative's design, development and implementation at global, regional and city levels. Our partners represent all sectors and they all respond to specific organisational and city needs. They include NGOs, professional associations, UN agencies, bilateral and multilateral agencies, private companies, governments and city leaders. In 2020, C/Can collaborated with over 70 partners which included Access Accelerated (representing 24 global biopharmaceutical companies) AdvaMed (representing Varian, Elekta and Accuray), the American Society of Clinical Oncology (ASCO), American Society of Clinical Pathology (ASCP), Amgen, Direct Relief, Icon Group, Sanofi Espoir Foundation, the National Cancer Institute - US, the University of Pittsburgh Medical Center (UPMC), the World Bank and the World Economic Forum and so many others. For more information please see <https://citycancerchallenge.org/>

Program Strategies & Activities

9 Strategies and activities

Strategy 1: Health Service Strengthening

ACTIVITY	DESCRIPTION
Planning	Cities completed a comprehensive needs assessment, prioritize objectives, and develop activity plans to address the prioritized objectives to improve access to quality cancer care.
Training	Cities are supported to strengthen the health workforce to deliver quality cancer care, including training through technical assistance and city-to-city knowledge exchanges.
Infrastructure	[No response provided]
Technology	[No response provided]
Management	[No response provided]
Funding	[No response provided]

Strategy 2: Financing

ACTIVITY	DESCRIPTION
Planning	<p>C/Can commissioned a comprehensive market assessment to analyze the need for and opportunity to advance sustainable financing for NCD infrastructure in low- and middle-income countries through impact investing.</p> <p>Cities work with the C/Can Technical Assistance to understand key information about the health financing landscape, connect with key financing stakeholders, and build capacity among healthcare leaders and policy makers.</p>

Strategy 3: Regulation & Legislation

ACTIVITY	DESCRIPTION
Advocacy	The enhancements and capabilities enabled by C/Can will enhance advocacy efforts in cities

Companies, Partners & Stakeholders

11 Company roles

COMPANY	ROLE
Access Accelerated	Provide seed funding, expertise, and in-kind support during all phases of the initiative's design, development and implementation at global, regional and city levels.
Roche	Co-creation of cancer care solutions
Bristol-Myers Squibb	Provision of funding and co-creation of cancer care solutions
Novartis	Provision of funding and co-creation of cancer care solutions
MSD	Provision of funding and co-creation of cancer care solutions
Sanofi	Provision of funding and co-creation of cancer care solutions
Takeda	Provision of funding for technical assistance and health finance initiatives
Chugai	Provision of funding for development of multidisciplinary treatment in Yangon, Myanmar

12 Funding and implementing partners

PARTNER	ROLE	SECTOR
Access Accelerated	Funding and implementing partner	Private
AdvaMed (representing Varian, Elekta, and Accuray)	Funding and implementing partner	Private
The World Bank	Implementing partner, provide financing expertise	Public
The World Economic Forum	Implementing partner, provide expertise, in-kind and financial support during all phases of the initiative's design, development and implementation at global, regional	Voluntary
The University of Pittsburgh Medical	Implementing partner, Provide expertise, in-kind and financial support during all phases of the initiative's design, development and implementation at global, regional	Voluntary
Amgen	Funding partner	Private
American Society of Clinical Oncology (ASCO)	Implementing partner, technical implementation support and capacity building	Voluntary

Companies, Partners & Stakeholders

12 Funding and implementing partners, cont.

PARTNER	ROLE	SECTOR
American Society of Clinical Pathology (ASCP)	Implementing partner, technical implementation support and capacity building	Voluntary
Direct Relief	Implementing partner	Voluntary
Dalberg	Implementing partner, provide financing expertise	Public
Icon Group	Funding partner	Private
National Cancer Institute (US)	Implementing partner technical implementation support and capacity building	Public
European Society for Radiotherapy and Oncology (ESTRO)	Implementing partner technical implementation support and capacity building	Voluntary
International Atomic Energy Agency (IAEA)	Implementing partner	Public
World Child Cancer	Implementing partner	Voluntary
Sanofi Espoir Foundation (SEF)	Funding and implementing partner	Public
University de Valle	Implementing partner	Public
WHO/PAHO	Implementing partner, provide financing expertise	Public
Local stakeholders	Implementing partners, serve on local working groups to identify needs and implementation priorities	Voluntary
National level stakeholders	Heads of State, First Lady, Ministries of Health, Ministries of Finance, Embassies, Development Agencies, National Cancer Institutes, national cancer societies, trade associations, insurance companies.	[No response provided]
Regional level stakeholders	Governor, Regional Health Secretary, Regional Chamber of Commerce, Foundations, City level: City Health Secretary, universities, NGOs, patient groups, healthcare providers, business leaders.	[No response provided]

13 Funding and implementing partners by country

[No response provided]

Companies, Partners & Stakeholders

14 Stakeholders

STAKEHOLDER	DESCRIPTION OF ENGAGEMENT	REQUESTED OR RECEIVED FROM STAKEHOLDER
Government	Inclusion of relevant national and local authorities in City Executive Committees. Commitment from the government is formalized in a signed Memorandum of Understanding.	Infrastructure: No Human Resources: No Funding: No Monitoring or Oversight: No Other resources: No
Non-Government Organization (NGO)	Inclusion of local NGOs in City Executive Committees. Commitment from civil society is formalized in a signed Memorandum of Understanding.	Infrastructure: No Human Resources: No Funding: No Monitoring or Oversight: No Other resources: No
Commercial Sector	Inclusion of local all relevant industry sectors - pharmaceutical, radiotherapy, imaging and diagnostics, hospital builders, finance.	Infrastructure: No Human Resources: No Funding: No Monitoring or Oversight: No Other resources: Yes
Local Hospitals/ Health Facilities	Inclusion of local hospitals and health facilities in the City Executive Committee. All local hospitals and health facilities are invited to participate in the engagement process, including the needs assessment, development of activity plans and implementation.	Infrastructure: No Human Resources: No Funding: No Monitoring or Oversight: No Other resources: No
Local Universities	Inclusion of local universities in City Executive Committee. University de Valle (Cali) is also an implementing partner.	Infrastructure: No Human Resources: No Funding: No Monitoring or Oversight: No Other resources: No

Local Context, Equity & Sustainability

15 Local health needs addressed by program

There are 18.1 million new cancer cases and over 9.6 million deaths worldwide each year¹; and these numbers are projected to rise rapidly over the next ten years. With 54% of the world's population living in urban areas², cities are uniquely positioned to drive sustainable innovation in the delivery of health services to large populations.

C/Can is transforming the global cancer treatment paradigm by engaging with cities with a population greater than one million to dramatically increase the number of people around the world with access to quality cancer services. City Cancer Challenge is a concrete response to the Sustainable Development Goals (SDGs) specifically, to achieve the shared vision of SDG 3 (health), SDG 11 (cities) and SDG 17 (partnerships), and the urgent need to champion a new way of working that unites different sectors, diverse interests and divergent agendas.

C/Can aims to increase the number of people with access to quality cancer treatment in cities around the world through a network of motivated partners including city leaders, governments, NGOs, UN agencies, and domestic and international businesses. It will contribute to meeting the global target to reduce premature deaths from Non-Communicable Diseases (NCD) by 25% by 2025, as improvements in early detection and the quality and access of treatment will be critical.

City Cancer Challenge has mobilised a network of global and local partners to develop and implement localised action plans, tailored to the needs of each city. Through the first four Key Learning Cities alone, these plans have the potential to improve care for over 32 million people.

To that end, the City Cancer Challenge model is already changing the way stakeholders from public and private sectors cooperate and collaborate with non-governmental actors to drive political commitment to cancer control at all levels of government, and build international support for implementing effective and targeted capacity-building for the health workforce. We are now poised to apply the early learnings in our first cities to achieve a global transformation of how quality cancer treatment and care is planned and delivered; the health workforce is trained; and health financing is mobilized through cross-sector partnerships that will meet our vision and the ambition of the SDGs.

a How needs were assessed

The C/Can City Needs assessment is conducted in all cities before project plans are developed and implemented. It is a robust needs assessment that provides an accurate picture of a city's current cancer treatment and care offer is a critical step in the C/Can 2025 process. It provides data that can inform the identification of a city's key capacities, major needs, and priority actions to address these gaps.

b Formal needs assessment conducted

Yes.

16 Social inequity addressed

The goal of C/Can is to improve access to quality cancer care at the city level, thus improving care for all. As patients from low- and middle-income households have fewer alternative options, this should help address social inequities. In particular, the outcome of improving access to quality treatment for all will contribute to addressing social inequities in access to cancer care. In addition, a significant financing gap exists for NCD treatment and care in LMICs, particularly for patients from low- and middle-income households. While the growing NCD burden drives demand for greater investment, current funding falls far short of meeting the need. Finding solutions to close the investment gap will be critical to providing sustainable, equitable, and quality NCD treatment and care. Cities work with the C/Can Technical Assistance to understand key information about the health financing landscape, connect with key financing stakeholders, and build capacity among healthcare leaders and policy makers.

Local Context, Equity & Sustainability

17 Local policies, practices, and laws considered during program design

POLICY, PRACTICE, LAW	APPLICABLE TO PROGRAM	DESCRIPTION OF HOW IT WAS TAKEN INTO CONSIDERATION
National regulations	Yes	Implementation is a local responsibility; relevant authorities are included in City Executive Committees.
Procurement procedures	[No response provided]	
Standard treatment guidelines	Yes	Availability and use are measured in each city, which is considered in defining and designing activities.
Quality and safety requirements	Yes	Availability and use are measured in each city, which is considered in defining and designing activities.
Remuneration scales and hiring practices	[No response provided]	
Other, please specify	Yes	Implementation is a local responsibility; relevant authorities are included in City Executive Committees.

18 How diversion of resources from other public health priorities are avoided

Involving ministries of health ensures that activities are aligned with existing National Cancer Control and NCD plans, ensuring an integrated approach to NCD management and harnessing national efforts towards Universal Health Coverage (UHC) and health system strengthening.

19 Program provides health technologies (medical devices, medicines, and vaccines)

No.

20 Health technology(ies) are part of local standard treatment guidelines

N/A

21 Health technologies are covered by local health insurance schemes

N/A

22 Program provides medicines listed on the National Essential Medicines List

N/A

Local Context, Equity & Sustainability

23 Sustainability plan

In 2020, based on a comprehensive literature review and learnings from the first learning city, Cali, C/Can developed a comprehensive Sustainability Framework outlining the key principles that are critical to sustain changes and achieve long-term impact in the cities beyond C/Can's direct support, including local ownership, leadership and political support; funding stability and diversity; capacity development and integration into local structures; effective communication with stakeholders; strategic planning; and monitoring, evaluation and learning. A Guidance for City Sustainability Planning for local stakeholders and a Sustainability Risk Management Framework to track risks that may impact the success of local sustainability partnerships and to identify mitigation strategies were also developed. Sustainability plans were developed for Cali, Asuncion, Yangon and Kumasi and are currently being implemented. Through these plans, C/Can supports city stakeholders to identify the sustainability model that works for their circumstances and what is needed to ensure their efforts to continue improving access to quality cancer care attract the necessary resources.

Additional Program Information

24 Additional program information

[No response provided]

a Potential conflict of interest discussed with government entity

[No response provided]

25 Access Accelerated Initiative participant

Yes.

26 International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) membership

No.

Resources

1 IARC, World Health Organisation, 2018, Press release No. 263, <https://www.who.int/cancer/PRGlobocanFinal.pdf?ua=1>, accessed March 7, 2019.

2. United Nations, Department of Economic and Social Affairs, Population Division, World urbanization prospects: the 2014 revision, highlights. <https://esa.un.org/unpd/wup/publications/files/wup2014-highlights.pdf> Date: 2014 (accessed Jan 6, 2017).

Program Indicators

PROGRAM NAME

C/Can 2025: – City Cancer Challenge

27 List of indicator data to be reported into Access Observatory database

INDICATOR	TYPE	STRATEGY	2017-2019	2020
1 Reduction in premature cancer mortality by 2030	Impact	Health Service Strengthening	79.2	---
2 Delivery of quality, equitable and sustainable cancer solutions in C/Can 2025 cities – Access	Outcome	Health Service Strengthening	480	---
3 Delivery of quality, equitable and sustainable cancer solutions in C/Can 2025 cities – Quality	Outcome	Health Service Strengthening	---	---
4 Total population covered	Output	Health Service Strengthening	42,870,000 people	---
5 Development and strengthening of cancer policies, protocols and processes	Output	Health Service Strengthening	7 guidelines, protocols or systems drafted/ developed	---
6 Healthcare professionals supported with technical assistance	Output	Health Service Strengthening	680 people	243 people
7 Technical experts providing technical assistance in cancer treatment and care	Output	Health Service Strengthening	98 people	---
8 Development of tools, guidance and protocols for cancer treatment and care	Output	Health Service Strengthening	12 guidelines, protocols or systems drafted/ developed	---
9 Number of investment cases and/or business models for project plans finalised and approved	Outcome	Health Service Strengthening	0 tools	2 tools
10 Cities collaborating to improve cancer treatment and care	Output	Health Service Strengthening	100%	---
11 Evidence used to support development of cancer treatment and care solutions	Output	Health Service Strengthening	---	10 tools

PROGRAM NAME

C/Can 2025: – City Cancer Challenge

27 List of indicator data to be reported into Access Observatory database cont.

INDICATOR		TYPE	STRATEGY	2017-2019	2017	2018	2020
12	Cities Engaged in the City Cancer Challenge	Activity	Health Service Strengthening	---	2 cities	6 cities	9 cities
13	Percentage of health facilities involved in identifying needs in cancer treatment	Activity	Health Service Strengthening	86.25%	---	---	---
14	Participation of healthcare professionals in identifying needs in cancer treatment	Activity	Health Service Strengthening	817 people	---	---	---
15	Participation of patients in identifying needs in cancer treatment and care	Activity	Health Service Strengthening	652 people	---	---	---
16	Needs assessment completed in cities	Activity	Health Service	4 needs	---	---	---
17	Technical assistance in cancer treatment and care provided	Activity	Health Service Strengthening	24 technical assistance events/ activities	---	---	31 technical assistance events/ activities
18	City development of project implementation plans	Activity	Health Service Strengthening	4 cities	---	---	---
19	Technical support provided to facilitate sustainable financing of cancer treatment and care	Activity	Health Service Strengthening	2 cities	---	---	2 cities
20	Technical experts contributing to technical support on sustainable financing for cancer treatment and care	Activity	Health Service Strengthening Financing	30 people	---	---	---

INDICATOR Reduction in cancer mortality by 2030

STRATEGY HEALTH SERVICE STRENGTHENING

ITEM	DESCRIPTION
Definition	Percentage of reduction of premature mortality from cancer in C/Can 2025 cities (or countries if city data is not available) by 2030
Method of measurement	Annual measures of premature cancer mortality reported by GLOBOCAN are subtracted from the cancer mortality at baseline (2018)
28 Data source	External public data
29 Frequency of reporting	Once per year

	RESPONSIBLE PARTY	DESCRIPTION	FREQUENCY
30 Data collection	GLOBOCAN (IARC)	<p>Uses A subsection of the Global Cancer Observatory (http://gco.iarc.fr), CANCER TODAY, which provides data visualization tools to explore the current scale and profile of cancer using estimates of the incidence, mortality, and prevalence of 36 specific cancer types and of all cancer sites combined in 185 countries or territories of the world in 2018, by sex and age group, as part of the GLOBOCAN project.</p> <p>The methods used to estimate the sex- and age-specific mortality rates of cancer in a specific country fall into the following broad categories, in order of priority:</p> <ul style="list-style-type: none"> • Observed national mortality rates were projected to 2018 (81 countries). • The most recently observed national mortality rates were applied to the 2018 population (20 countries). • Rates were estimated from the corresponding national incidence estimates by modelling, using incidence-to-mortality ratios derived from cancer registries in neighbouring countries (81 countries). • Rates were estimated as an average of those from selected neighbouring countries (3 countries). <p>The complete sources of information and methods used to estimate the global incidence and mortality in 2018 together with their uncertainty intervals (for all ages) can be found in Ferlay et al. (2018).</p> <p>Please see here for further details.</p>	Ongoing

INDICATOR **Reduction in cancer mortality by 2030**

STRATEGY HEALTH SERVICE STRENGTHENING

1

	RESPONSIBLE PARTY	DESCRIPTION	FREQUENCY
31 Data processing	GLOBOCAN (IARC)	Please see here for further details. https://gicr.iarc.fr/	Ongoing
32 Data validation		[No response provided]	

33 Challenges in data collection and steps to address challenges

Caution must be exercised when interpreting these estimates, given the limited quality and coverage of cancer data worldwide at present, particularly in low- and middle-income countries. International Agency for Research on Cancer (IARC) approach is not only to evaluate, compile, and use the data from the Agency's collaborators in these estimates but also to work alongside national staff to improve local data quality, registry coverage, and analytical capacity.

Collecting robust data requires aligning with independent local stakeholders for data collection, a strong M&E framework, detailed operating processing, and training. It requires expertise, time, and effort. One limitation of this indicator is that it will be difficult to attribute any changes in mortality to the program alone because there may be other factors outside the program that have contributed to change in mortality.

INDICATOR	2017-2019	2020
1 Reduction in cancer mortality by 2030	79.2	---

Comments: Date available from source is from 2018.

ITEM	DESCRIPTION
Definition	Percentage of cities showing progress in access to quality cancer treatment and care from the viewpoint of: i) civil society/patient advocacy organisations, patients; ii) institutional staff
Method of measurement	Measurement against a sub-set of criteria of access (using the City Needs Assessment as a baseline) using a survey for patients and civil society and a questionnaire for institutional staff of participating health institutions. Calculation: $\frac{\text{Number of cities showing progress in access to cancer treatment}}{\text{Total number of cities involved in the program}}$
28 Data source	Routine program data
29 Frequency of reporting	Once per year

	RESPONSIBLE	DESCRIPTION	FREQUENCY
30 Data collection	Company	City Manager coordinates technical committees to collect data on the outcome indicators (focused on quality and access) from participating healthcare facilities, civil society organisations and patients using a survey. Data is collected over the months of September and October each year.	Once per year
31 Data processing	Company	A City Manager in each city coordinates the distribution and collection of the survey/questionnaire once a year. The data is then sent to the Monitoring, Evaluation and Learning (MEL) Manager who conducts the data analysis within one month by dividing the number of cities showing progress in access to quality cancer treatment and care by the total number of cities involved in the program. The MEL Manager compiles and shares the results with the City Cancer Challenge team to use in reporting as appropriate.	Once per year
32 Data validation		Formative evaluation to be conducted in late 2019/ early 2020 and mid-term evaluation on 2021 will evaluate the fidelity to program implementation, including data collection and reporting.	

INDICATOR **Delivery of quality, equitable and sustainable cancer solutions in C/Can 2025 cities - Access**

2

STRATEGY HEALTH SERVICE STRENGTHENING

33 Challenges in data collection and steps to address challenges

Collecting robust data requires aligning with independent local stakeholders for data collection, a strong M&E framework, detailed operating processing, and training. It requires expertise, time, and effort.

INDICATOR	2017-2019	2020
2 Delivery of quality, equitable and sustainable cancer solutions in C/Can 2025 cities - Access	480	---

Comments: Not available until 2021.

ITEM	DESCRIPTION
Definition	Percentage of C/Can 2025 cities showing progress in quality related sub-criteria of <ol style="list-style-type: none"> 1. Health workforce 2. Data acquisition and management 3. Evidence-based protocols for care 4. Multidisciplinary treatment planning 5. Safety and occupational hazards; 6. Patient engagement 7. Care pathway
Method of measurement	Measurement against a sub-set of criteria of quality (using the City Needs Assessment as a baseline) using a survey for patients and civil society and a questionnaire for institutional staff of participating health institutions. Calculation: $\frac{\text{Number of cities showing progress in quality related sub-criteria}}{\text{Total number of cities involved in the program}}$
28 Data source	Routine program data
29 Frequency of reporting	Once per year

	RESPONSIBLE PARTY	DESCRIPTION	FREQUENCY
30 Data collection	Company	City Manager coordinates technical committees to collect data on the outcome indicators (focused on quality and access) from participating healthcare facilities, civil society organisations and patients using a survey. Data is collected over the months of September and October each year.	Once per year
31 Data processing	Company	A City Manager in each city coordinates the distribution and collection of the survey/questionnaire once a year. The data is then sent to the Monitoring, Evaluation and Learning (MEL) Manager who conducts the data analysis within one month by dividing the number of C/Can 2025 cities showing progress in quality related sub-criteria by the total number of cities in the program. The MEL Manager compiles and shares the results with the City Cancer Challenge team to use in reporting as appropriate.	Once per year
32 Data validation		Formative evaluation to be conducted in late 2019/early 2020 and mid-term evaluation on 2021 will evaluate the fidelity to program implementation, including data collection and reporting.	

33 Challenges in data collection and steps to address challenges

C/Can projects in cities are led by local stakeholders. Therefore collecting robust data requires aligning with independent local stakeholders for data collection based on the local context, including data availability, capacity and structure of the healthcare system. This required a robust M&E framework for projects that are developed in collaboration with local stakeholder, and supported with ongoing technical support and standardized processes.

INDICATOR	2017-2019	2020
3 Delivery of quality, equitable and sustainable cancer solutions in C/Can 2025 cities - Quality	---	---

Comments: Data not available until 2020.

ITEM	DESCRIPTION
Definition	The total number of people benefitting from the improved quality of infrastructure and services for cancer treatment and care in cities.
Method of measurement	Counting of populations covered by health facilities in the cities.
28 Data source	External public data
29 Frequency of reporting	Once per year

	RESPONSIBLE PARTY	DESCRIPTION	FREQUENCY
30 Data collection	National governments	Each city's City Manager reports the total population served by health facilities in the city as part of the City Profile document that is created in the first few months of a city's engagement with the City Cancer Challenge.	Every three months
31 Data processing	National governments	City Managers report the total population served of their city once as part of the City Profile document created at the beginning of the engagement with the City Cancer Challenge. This is then aggregated globally by the Monitoring, Evaluation and Learning Manager every 3 months.	Ongoing
32 Data validation		Formative evaluation to be conducted in late 2019/ early 2020 and mid-term evaluation on 2021 will evaluate the fidelity to program implementation, including data collection and reporting.	

33 Challenges in data collection and steps to address challenges

C/Can projects in cities are led by local stakeholders. Therefore collecting robust data requires aligning with independent local stakeholders for data collection based on the local context, including data availability, capacity and structure of the healthcare system. This required a robust M&E framework for projects that are developed in collaboration with local stakeholder, and supported with ongoing technical support and standardized processes.

INDICATOR	2017-2019	2020
4 Total population served	42,870,000 people	---

Comments: N/A

INDICATOR **Development and strengthening of cancer policies, protocols, and processes**

5

STRATEGY HEALTH SERVICE STRENGTHENING

ITEM	DESCRIPTION
Definition	Number of policies, protocols, systems and/or processes that have been strengthened or developed as a result of dialogue, coordination and cooperation among key institutions and stakeholders through the City Cancer Challenge
Method of measurement	Reported by each city in quarterly output reports
28 Data source	[No response provided]
29 Frequency of reporting	Once per year

	RESPONSIBLE PARTY	DESCRIPTION	FREQUENCY
30 Data collection	Company	Each city's City Manager reports every three months by counting the number of policies, protocols and/or processes that have been developed or strengthened to the Monitoring, Evaluation and Learning Manager using a standard reporting template. The Monitoring, Evaluation and Learning Manager then checks the data quality and follows up with City Managers on any gaps identified. The Monitoring, Evaluation and Learning Managers records the reports in a database so the data can be analysed and aggregated globally.	Every three months
31 Data processing	Company	City Managers report every 3 months using a City Output Report Form. This is then aggregated globally by the Monitoring, Evaluation and Learning Manager every 3 months.	Ongoing
32 Data validation		Formative evaluation to be conducted in late 2019/early 2020 and mid-term evaluation on 2021 will evaluate the fidelity to program implementation, including data collection and reporting.	

33 Challenges in data collection and steps to address challenges

C/Can projects in cities are led by local stakeholders. Therefore collecting robust data requires aligning with independent local stakeholders for data collection based on the local context, including data availability, capacity and structure of the healthcare system. This required a robust M&E framework for projects that are developed in collaboration with local stakeholder, and supported with ongoing technical support and standardized processes.

INDICATOR	2017-2019	2020
5 Development and strengthening of cancer policies, protocols, and processes	7 guidelines, protocols or systems drafted/developed	---

Comments: N/A

INDICATOR **Healthcare professionals supported with technical assistance**

6

STRATEGY HEALTH SERVICE STRENGTHENING

ITEM	DESCRIPTION
Definition	Number of individuals supported with technical assistance through the City Cancer Challenge
Method of measurement	Count of participants at technical assistance activities such as workshops, trainings, coaching sessions, etc
28 Data source	Routine program data
29 Frequency of reporting	Once per year

	RESPONSIBLE PARTY	DESCRIPTION	FREQUENCY
30 Data collection	Company	Each city's City Manager reports every three months by counting the number of individuals that have been supported by various form of technical assistance to the Monitoring, Evaluation and Learning Manager using a standard reporting template. The Monitoring, Evaluation and Learning Manager then checks the data quality and follows up with City Managers on any gaps identified. The Monitoring, Evaluation and Learning Managers records the reports in a database so the data can be analysed and aggregated globally.	Every three months
31 Data processing	Company	City Managers report every 3 months using a City Output Report Form. This is then aggregated globally by the Monitoring, Evaluation and Learning Manager every 3 months.	Ongoing
32 Data validation		Formative evaluation to be conducted in late 2019/ early 2020 and mid-term evaluation on 2021 will evaluate the fidelity to program implementation, including data collection and reporting.	

33 Challenges in data collection and steps to address challenges

C/Can projects in cities are led by local stakeholders. Therefore collecting robust data requires aligning with independent local stakeholders for data collection based on the local context, including data availability, capacity and structure of the healthcare system. This required a robust M&E framework for projects that are developed in collaboration with local stakeholder, and supported with ongoing technical support and standardized processes.

INDICATOR	2017	2020
6 Healthcare professionals supported with technical assistance	680 people	243 people

Comments: 2020: Cali, Colombia; Asuncion, Paraguay; Yangon, Myanmar; Kumasi, Ghana.

ITEM	DESCRIPTION
Definition	Number of technical experts providing technical assistance.
Method of measurement	Count of technical experts conducting/facilitating technical assistance activities such as workshops, trainings, coaching sessions, etc.
28 Data source	Routine program data
29 Frequency of reporting	Once per year

	RESPONSIBLE PARTY	DESCRIPTION	FREQUENCY
30 Data collection	Company	Each city's City Manager reports every three months by counting the number of individuals that have been involved in providing and/or facilitating various form of technical assistance to the Monitoring, Evaluation and Learning Manager using a standard reporting template. The Monitoring, Evaluation and Learning Manager then checks the data quality and follows up with City Managers on any gaps identified. The Monitoring, Evaluation and Learning Managers records the reports in a database, so the data can be analysed and aggregated globally.	Every three months
31 Data processing	Company	City Managers report every 3 months using a City Output Report Form. This is then aggregated globally by the Monitoring, Evaluation and Learning Manager every 3 months.	Ongoing
32 Data validation		Formative evaluation to be conducted in late 2019/early 2020 and mid-term evaluation on 2021 will evaluate the fidelity to program implementation, including data collection and reporting.	

33 Challenges in data collection and steps to address challenges

C/Can projects in cities are led by local stakeholders. Therefore collecting robust data requires aligning with independent local stakeholders for data collection based on the local context, including data availability, capacity and structure of the healthcare system. This required a robust M&E framework for projects that are developed in collaboration with local stakeholder, and supported with ongoing technical support and standardized processes.

INDICATOR

2017-2019

2020

7	Technical experts providing technical assistance in cancer treatment and care	98 people	---
---	---	-----------	-----

Comments: N/A

INDICATOR **Development of tools, guidance and protocols for cancer treatment and care**



STRATEGY HEALTH SERVICE STRENGTHENING

ITEM	DESCRIPTION
Definition	Number of specific products (tools, processes, guidance, protocols, standards, systems) developed for cancer care and treatment as a result of technical assistance.
Method of measurement	Count of specific products developed or under development for cancer treatment and care as a direct result of technical assistance in program activities.
28 Data source	Routine program data
29 Frequency of reporting	Once per year

	RESPONSIBLE PARTY	DESCRIPTION	FREQUENCY
30 Data collection	Company	Each city's City Manager reports every three months by counting the number of tools that have been developed as a result of technical assistance activities to the Monitoring, Evaluation and Learning Manager using a standard reporting template. The Monitoring, Evaluation and Learning Manager then checks the data quality and follows up with City Managers on any gaps identified. The Monitoring, Evaluation and Learning Managers records the reports in a database so the data can be analysed and aggregated globally.	Every three months
31 Data processing	Company	City Managers report every 3 months using a City Output Report Form. This is then aggregated globally by the Monitoring, Evaluation and Learning Manager every 3 months.	Ongoing
32 Data validation		Formative evaluation to be conducted in late 2019/early 2020 and mid-term evaluation on 2021 will evaluate the fidelity to program implementation, including data collection and reporting.	

33 Challenges in data collection and steps to address challenges

Collecting robust data requires aligning with independent local stakeholders for data collection, a strong M&E framework, detailed operating processing, and training. It requires expertise, time, and effort.

INDICATOR	2017-2019	2020
8 Development of tools, guidance and protocols for cancer treatment and care	12 guidelines, protocols or systems drafted/developed	---

Comments: N/A

Number of investment cases and/or business models for project plans finalised and approved

ITEM	DESCRIPTION
Definition	Number of sustainable financing investment cases or business models developed for cancer care activities as a result of C/Can support for project plans.
Method of measurement	Count of number of investment cases or business models developed as a result of program activities.
28 Data source	Routine program data
29 Frequency of reporting	Once per year

	RESPONSIBLE PARTY	DESCRIPTION	FREQUENCY
30 Data collection	Company	Each city's City Manager reports every three months by counting the number of sustainable financing mechanisms developed in the city to the Monitoring, Evaluation and Learning Manager using a standard reporting template. The Monitoring, Evaluation and Learning Manager then checks the data quality and follows up with City Managers on any gaps identified. The Monitoring, Evaluation and Learning Managers records the reports in a database so the data can be analysed and aggregated globally.	Every three months
31 Data processing	Company	City Managers report every 3 months using a City Output Report Form. This is then aggregated globally by the Monitoring, Evaluation and Learning Manager every 3 months.	Ongoing
32 Data validation		Formative evaluation to be conducted in late 2019/ early 2020 and mid-term evaluation on 2021 will evaluate the fidelity to program implementation, including data collection and reporting.	

33 Challenges in data collection and steps to address challenges

Collecting robust data requires aligning with independent local stakeholders for data collection, a strong M&E framework, detailed operating processing, and training. It requires expertise, time, and effort.

INDICATOR	2019	2020
9 Number of investment cases and/or business models for project plans finalised and approved	0 tools	2 tools

Comments: 2 investment cases are currently under development.

ITEM	DESCRIPTION
Definition	Percent of C/Can 2025 cities collaborating with other cities to improve cancer care and treatment at city, regional and global levels.
Method of measurement	Count of cities attending city-city collaboration events and desk review of case studies on collaboration reported. Calculation: $\frac{\text{Number of cities collaborating with other cities}}{\text{Total number of cities involved in the program}}$
28 Data source	Non-routine program data
29 Frequency of reporting	Once per year

	RESPONSIBLE PARTY	DESCRIPTION	FREQUENCY
30 Data collection	Company	City Managers report every 3 months using a City Output Report Form. This is then aggregated globally by the Monitoring, Evaluation and Learning Manager every 3 months.	Once per year
31 Data processing	Company	Count of cities attending city-city collaboration events conducted by the Monitoring, Evaluation and Learning Manager using attendance records, participant lists and event reports. Any case studies on collaboration events will also be reviewed as part of the desk review.	Once per year
32 Data validation		Formative evaluation to be conducted in late 2019/ early 2020 and mid-term evaluation on 2021 will evaluate the fidelity to program implementation, including data collection and reporting.	

33 Challenges in data collection and steps to address challenges

Collecting robust data requires aligning with independent local stakeholders for data collection, a strong M&E framework, detailed operating processing, and training. It requires expertise, time, and effort.

INDICATOR	2017-2019	2020
10 Cities collaborating to improve cancer treatment and care	100%	---

Comments: Cali, Colombia; Asuncion, Paraguay; Yangon, Myanmar; Kumasi, Ghana; Porto Alegre, Brazil; Tbilisi, Georgia; Kigali, Rwanda

ITEM	DESCRIPTION
Definition	Number of cancer solutions developed based on quality evidence produced by C/Can
Method of measurement	Count of cancer solutions reported in surveys to have been developed using evidence produced by C/Can
28 Data source	Non-routine program data
29 Frequency of reporting	Once per year

	RESPONSIBLE PARTY	DESCRIPTION	FREQUENCY
30 Data collection	Company	The Monitoring, Evaluation and Learning Manager emails an annual anonymous online survey to all users of data sharing products such as the C/Can website and data platform. The results are then analysed by the Monitoring, Evaluation and Learning Manager.	Once per year
31 Data processing	Company	Analyzed once a year by the Monitoring, Evaluation and Learning Manager using SurveyMonkey by counting the total number of solutions reported to be developed based on C/Can provided evidence/data. The results are then recorded in a database.	Ongoing
32 Data validation		Formative evaluation to be conducted in late 2019/early 2020 and mid-term evaluation on 2021 will evaluate the fidelity to program implementation, including data collection and reporting.	

33 Challenges in data collection and steps to address challenges

Collecting robust data requires aligning with independent local stakeholders for data collection, a strong M&E framework, detailed operating processing, and training. It requires expertise, time, and effort. An additional challenge could be low response rates to the survey invitation.

INDICATOR	2017-2019	2020
11 Evidence used to support development of cancer treatment and care solutions	---	10 tools

Comments: 2020: 10 specialized training packaged in developed base don evidence gathered and lessons learned

ITEM	DESCRIPTION
Definition	Number of cities engaged in the City Cancer Challenge.
Method of measurement	Count of all cities selected to participate in the initiative.
28 Data source	Routine program data
29 Frequency of reporting	Once per year

	RESPONSIBLE PARTY	DESCRIPTION	FREQUENCY
30 Data collection	Company	The Monitoring, Evaluation counts the number of cities formally engaged with the City Cancer Challenge by counting the total number of signed Memoranda of Understanding between the cities and the City Cancer Challenge.	Ongoing
31 Data processing	Company	Analyzed once a year by the Monitoring, Evaluation and Learning Manager and the results are then recorded in a database.	Ongoing
32 Data validation		Formative evaluation to be conducted in late 2019/ early 2020 and mid-term evaluation on 2021 will evaluate the fidelity to program implementation, including data collection and reporting.	

33 Challenges in data collection and steps to address challenges

Collecting robust data requires aligning with independent local stakeholders for data collection, a strong M&E framework, detailed operating processing, and training. It requires expertise, time, and effort.

INDICATOR	2017	2018	2020
12 Cities engaged in the City Cancer Challenge	2 cities	6 cities	9 cities

Comments: Cali, Colombia; Asuncion, Paraguay; Yangon, Myanmar; Kumasi, Ghana; Porto Alegre, Brazil; Tbilisi, Georgia; Kigali, Rwanda; Leon, Mexico; Greater Petaling, Malaysia.

INDICATOR **Percentage of health facilities involved in identifying needs in cancer treatment and care**

13

STRATEGY HEALTH SERVICE STRENGTHENING

ITEM	DESCRIPTION
Definition	Percentage of identified cancer treatment and care facilities participating in the City Needs Assessment.
Method of measurement	Number of health facilities participating in the needs assessment divided by the total number of identified health facilities.
28 Data source	Routine program data
29 Frequency of reporting	Once per year

	RESPONSIBLE PARTY	DESCRIPTION	FREQUENCY
30 Data collection	Company	Each City Manager record a list of institutions that participate in the needs assessment process, which is shared in the final results document called the Situation Analysis. The Monitoring, Evaluation and Learning Manager will, every 3 months, count the total number of reported participating institutions in the Situational Analysis reports from all cities.	Ongoing
31 Data processing	Company	Analyzed once a year by the Monitoring, Evaluation and Learning Manager by summing the health facilities that participated in the needs assessment. The results are then recorded in a database.	Every three months
32 Data validation		Formative evaluation to be conducted in late 2019/ early 2020 and mid-term evaluation on 2021 will evaluate the fidelity to program implementation, including data collection and reporting.	

33 Challenges in data collection and steps to address challenges

Collecting robust data requires aligning with independent local stakeholders for data collection, a strong M&E framework, detailed operating processing, and training. It requires expertise, time, and effort.

INDICATOR	2017-2019	2020
13 Participation of health facilities in identifying needs in cancer treatment and care	86.25%	---

Comments: Simple (non-weighted) average.

ITEM	DESCRIPTION
Definition	Number of healthcare professionals involved in needs assessment.
Method of measurement	Count of all healthcare professionals participating in City Needs Assessment at city level.
28 Data source	Routine program data
29 Frequency of reporting	Once per year

	RESPONSIBLE PARTY	DESCRIPTION	FREQUENCY
30 Data collection	Company	Each City Manager record a list of healthcare professionals that participate in the needs assessment process, which is shared in the final results document called the Situation Analysis. The Monitoring, Evaluation and Learning Manager will, every 3 months, count the total number of reported participating healthcare professionals in the Situational Analysis reports from all cities.	Ongoing
31 Data processing	Company	Analyzed once a year by the Monitoring, Evaluation and Learning Manager by summing the healthcare professionals that participated in the needs assessment. The results are then recorded in a database.	Every three months
32 Data validation		Formative evaluation to be conducted in late 2019/ early 2020 and mid-term evaluation on 2021 will evaluate the fidelity to program implementation, including data collection and reporting.	

33 Challenges in data collection and steps to address challenges

Collecting robust data requires aligning with independent local stakeholders for data collection, a strong M&E framework, detailed operating processing, and training. It requires expertise, time, and effort.

INDICATOR

2017-2019

2020

14 Participation of healthcare professionals in identifying needs in cancer treatment and care	817 people	---
--	------------	-----

Comments: N/A

INDICATOR **Participation of patients in identifying needs in cancer treatment and care**

15

STRATEGY HEALTH SERVICE STRENGTHENING

ITEM	DESCRIPTION
Definition	Number of patients involved in needs assessment.
Method of measurement	Count of all patients and civil society organizations participating in City Needs Assessment at city level.
28 Data source	Routine program data
29 Frequency of reporting	Once per year

	RESPONSIBLE PARTY	DESCRIPTION	FREQUENCY
30 Data collection	Company	Each City Manager records the number of patients that participate in the needs assessment process, which is shared in the final results document called the Situation Analysis. The Monitoring, Evaluation and Learning Manager will, every 3 months, count the total number of reported participating patients in the Situational Analysis reports from all cities.	Ongoing
31 Data processing	Company	Analyzed once a year by the Monitoring, Evaluation and Learning Manager by summing the patients that participated in the needs assessment. The results are then recorded in a database.	Every three months
32 Data validation		Formative evaluation to be conducted in late 2019/ early 2020 and mid-term evaluation on 2021 will evaluate the fidelity to program implementation, including data collection and reporting.	

33 **Challenges in data collection and steps to address challenges**

Collecting robust data requires aligning with independent local stakeholders for data collection, a strong M&E framework, detailed operating processing, and training. It requires expertise, time, and effort.

INDICATOR	2017-2019	2020
15 Participation of patients in identifying needs in cancer treatment and care	652 people	---

Comments: N/A

ITEM	DESCRIPTION
Definition	Number of cities with completed needs assessments.
Method of measurement	Count of all participating cities that have completed the needs assessment process.
28 Data source	Routine program data
29 Frequency of reporting	Once per year

	RESPONSIBLE PARTY	DESCRIPTION	FREQUENCY
30 Data collection	Company	Each city's City Manager reports every three months on whether the Needs Assessment Process has been completed to the Monitoring, Evaluation and Learning Manager using a standard reporting template. The Monitoring, Evaluation and Learning Manager then checks the data quality and follows up with City Managers on any gaps identified. The Monitoring, Evaluation and Learning Managers records the reports in a database so the data can be analysed and aggregated globally.	Every three months
31 Data processing	Company	City Managers report every 3 months using a City Output Report Form. This is then aggregated globally by the Monitoring, Evaluation and Learning Manager every 3 months.	Ongoing
32 Data validation		Formative evaluation to be conducted in late 2019/ early 2020 and mid-term evaluation on 2021 will evaluate the fidelity to program implementation, including data collection and reporting.	

33 Challenges in data collection and steps to address challenges

Collecting robust data requires aligning with independent local stakeholders for data collection, a strong M&E framework, detailed operating processing, and training. It requires expertise, time, and effort.

INDICATOR	2017-2019	2020
16 Needs assessment completed in cities	4	---

Comments: Cali, Colombia; Asuncion, Paraguay; Yangon, Myanmar; Kumasi, Ghana

ITEM	DESCRIPTION
Definition	Number of technical assistance activities.
Method of measurement	Count of all technical assistance related activities conducted as part of the program.
28 Data source	Routine program data
29 Frequency of reporting	Once per year

	RESPONSIBLE PARTY	DESCRIPTION	FREQUENCY
30 Data collection	Company	Each city's City Manager reports every three months on the number of technical assistance activities that have been conducted to the Monitoring, Evaluation and Learning Manager using a standard reporting template. The Monitoring, Evaluation and Learning Manager then checks the data quality and follows up with City Managers on any gaps identified. The Monitoring, Evaluation and Learning Managers records the reports in a database so the data can be analysed and aggregated globally.	Every three months
31 Data processing	Company	City Managers report every 3 months using a City Output Report Form. This is then aggregated globally by the Monitoring, Evaluation and Learning Manager every 3 months.	Ongoing
32 Data validation		Formative evaluation to be conducted in late 2019/ early 2020 and mid-term evaluation on 2021 will evaluate the fidelity to program implementation, including data collection and reporting.	

33 Challenges in data collection and steps to address challenges

Collecting robust data requires aligning with independent local stakeholders for data collection, a strong M&E framework, detailed operating processing, and training. It requires expertise, time, and effort.

INDICATOR

2017-2019

2020

17 Technical assistance in cancer treatment and care provided	24 Technical assistance events/ activities	31 Technical assistance events/ activities
---	--	--

Comments: 2020: 31 capacity building workshops .

ITEM	DESCRIPTION
Definition	Number of cities with project implementation plans developed for prioritised objectives.
Method of measurement	Count of all participating cities that have developed project implementation plans for the program activities.
28 Data source	Routine program data
29 Frequency of reporting	Once per year

	RESPONSIBLE PARTY	DESCRIPTION	FREQUENCY
30 Data collection	Company	Each city's City Manager reports every three months to the Monitoring, Evaluation and Learning Manager using a standard reporting template on how many of the identified priority objectives have project implementation plans. This City Manager gathers evidence from the number of project implementation plan documents are completed and available compared the total number of prioritised objectives (each objective is expected to have it's respective project implementation plan). The Monitoring, Evaluation and Learning Manager then checks the data quality and follows up with City Managers on any gaps identified. The Monitoring, Evaluation and Learning Managers records the reports in a database so the data can be analysed and aggregated globally.	Every three months
31 Data processing	Company	City Managers report every 3 months using a City Output Report Form. This is then aggregated globally by the Monitoring, Evaluation and Learning Manager every 3 months.	Ongoing
32 Data validation		Formative evaluation to be conducted in late 2019/early 2020 and mid-term evaluation on 2021 will evaluate the fidelity to program implementation, including data collection and reporting.	

33 Challenges in data collection and steps to address challenges

Collecting robust data requires aligning with independent local stakeholders for data collection, a strong M&E framework, detailed operating processing, and training. It requires expertise, time, and effort.

INDICATOR	2017-2019	2020
18 City development of project implementation plans	4 cities	---

Comments: Cali, Colombia; Asuncion, Paraguay; Yangon, Myanmar; Kumasi, Ghana

ITEM	DESCRIPTION
Definition	Number of cities in which the City Health Financing Lab has/is facilitating sustainable financing mechanisms.
Method of measurement	Count of all cities in which the City Health Financing Lab is facilitating sustainable financing of cancer treatment and care.
28 Data source	Routine program data
29 Frequency of reporting	Once per year

	RESPONSIBLE PARTY	DESCRIPTION	FREQUENCY
30 Data collection	Company	The City Health Financing Lead counts the number of cities the City Health Financing Lab is working with, which is reported in the Annual City Health Financing Lab report. This is then used as a data source by the Monitoring, Evaluation and Learning Manager during annual data collection, in addition they all ask the City Health Financing Lead to confirm that the data is accurate.	Every three months
31 Data processing	Company	City Managers report every 3 months using a City Output Report Form. This is then aggregated globally by the Monitoring, Evaluation and Learning Manager every 3 months.	Ongoing
32 Data validation		Formative evaluation to be conducted in late 2019/ early 2020 and mid-term evaluation on 2021 will evaluate the fidelity to program implementation, including data collection and reporting.	

33 Challenges in data collection and steps to address challenges

C/Can projects in cities are led by local stakeholders. Therefore collecting robust data requires aligning with independent local stakeholders for data collection based on the local context, including data availability, capacity and structure of the healthcare system. This required a robust M&E framework for projects that are developed in collaboration with local stakeholder, and supported with ongoing technical support and standardized processes.

INDICATOR

2017-2019 2020

19 Technical support provided to facilitate sustainable financing of cancer support and treatment	2 cities	2 cities
---	----------	----------

Comments: Cali, Colombia; Asuncion, Paraguay; Yangon, Myanmar

INDICATOR **Technical experts contributing to technical support on sustainable financing for cancer treatment and care**

20

STRATEGY HEALTH SERVICE STRENGTHENING, FINANCING

ITEM	DESCRIPTION
Definition	Number of relevant experts contributing to the City Health Financing Lab advisory committee.
Method of measurement	Count of experts in the City Health Financing Lab advisory committee.
28 Data source	Routine program data
29 Frequency of reporting	Once per year

	RESPONSIBLE PARTY	DESCRIPTION	FREQUENCY
30 Data collection	Company	The City Health Financing Lead counts the technical experts on the City Health Financing Lab advisory committee is working with, which is reported in the Annual City Health Financing Lab report. This is then used as a data source by the Monitoring, Evaluation and Learning Manager during annual data collection, in addition they all ask the City Health Financing Lead to confirm that the data is accurate.	Once per year
31 Data processing	Company	The City Health Financing Leads reports on the number of experts in the network once a year though the CHFL Annual Report. This is then recorded by the Monitoring, Evaluation and Learning Manager.	Ongoing
32 Data validation		Formative evaluation to be conducted in late 2019/ early 2020 and mid-term evaluation on 2021 will evaluate the fidelity to program implementation, including data collection and reporting.	

33 Challenges in data collection and steps to address challenges

C/Can projects in cities are led by local stakeholders. Therefore collecting robust data requires aligning with independent local stakeholders for data collection based on the local context, including data availability, capacity and structure of the healthcare system. This required a robust M&E framework for projects that are developed in collaboration with local stakeholder, and supported with ongoing technical support and standardized processes.

INDICATOR	2017-2019	2020
20 Technical experts contributing to technical support on sustainable financing for cancer treat-	30 people	---

Comments: N/A

Appendix

This program report is based on the information gathered from the Access Observatory questionnaire below.

Program Description

PROGRAM OVERVIEW

1 Program Name

2 Diseases program aims to address:

Please identify the disease(s) that your program aims to address (select all that apply).

3 Beneficiary population

Please identify the beneficiary population of this program (select all that apply).

4 Countries

Please select all countries that this program is being implemented in (select all that apply).

5 Program Start Date

6 Anticipated Program Completion Date

7 Contact person

On the public profile for this program, if you would like to display a contact person for this program, please list the name and email address here (i.e. someone from the public could email with questions about this program profile and data).

8 Program summary

Please provide a brief summary of your program including program objectives (e.g., the intended purposes and expected results of the program; if a pilot program, please note this). Please provide a URL, if available. Please limit replies to 750 words.

PROGRAM STRATEGIES & ACTIVITIES

9 Strategies and activities

Based on the BUSPH Taxonomy of Strategies, which strategy or strategies apply to your program (please select all that apply)?

10 Strategy by country

If you have registered one program for multiple countries, this question allows you to provide a bit more specificity about each country (e.g. some countries have different strategies, diseases, partners, etc.). Please complete these tables as applicable. For each portion you have you selected from above (program strategies), please identify which country/countries these apply.

COMPANIES, PARTNERS AND STAKEHOLDERS

11 Company roles

Please identify all pharmaceutical companies, including yours, who are collaborating on this program:

What role does each company play in the implementation of your program?

12 Funding and implementing partners

Please identify all funding and implementing partners who are supporting the implementation of this program (Implementing partners is defined as either an associate government or non-government entity or agency that supplements the works of a larger organization or agency by helping to carry out institutional arrangements in line with the larger organization's goals and objectives.)

a. What role does each partner play in the implementation of your program? Please give background on the organization and describe the nature of the relationship between the organization and your company. Describe the local team's responsibilities for the program, with reference to the program strategies and activities. (response required for each partner selected).

b. For each partner, please categorize them as either a Public Sector, Private Sector, or Voluntary Sector partner.

(Public Sector is defined as government; Private Sector is defined as A business unit established, owned, and operated by private individuals for profit, instead of by or for any government or its agencies. Generation and return of profit to its owners or shareholders is emphasized; Voluntary Sector is defined as Organizations whose purpose is to benefit and enrich society, often without profit as a motive and with little or no government intervention. Unlike the private sector where the generation and return of profit to its owners is emphasized, money raised or earned by an organization in the voluntary sector is usually invested back into the community or the organization itself (ex. Charities, foundations, advocacy groups etc.))

c. Please provide the URL to the partner organizations' webpages

13 Funding and implementing partners by country

If you have registered one program for multiple countries, this question allows you to provide a bit more specificity about each country (e.g., some countries have different strategies, diseases, partners, etc.). Please complete these tables as applicable. For each portion you have selected from above (funding and implementing partners), please identify which country/countries these apply.

14 Stakeholders

Please describe how you have engaged with any of these local stakeholders in the planning and/or implementation of this program. (Stakeholders defined as individuals or entities who are involved in or affected by the execution or outcome of a project and may have influence and authority to dictate whether a project is a success or not (ex. Ministry of Health, NGO, Faith-based organization, etc.). Select all that apply.

- Government, please explain
- Non-Government Organization (NGO), please explain
- Faith-based organization, please explain
- Commercial sector, please explain
- Local hospitals/health facilities, please explain
- Local universities, please explain
- Other, please explain

LOCAL CONTEXT, EQUITY & SUSTAINABILITY

15 Local health needs addressed by program

Please describe how your program is responsive to local health needs and challenges (e.g., how you decided and worked together with local partners to determine that this program was appropriate for this context)?

a How were needs assessed

b Was a formal need assessment conducted

(Yes/No) If yes, please upload file or provide URL.

16 Social inequity addressed

Does your program aim to address social inequity in any way (if yes, please explain). (Inequity is defined as lack of fairness or justice. Sometime 'social disparities,' 'structural barriers' and 'oppression and discrimination' are used to describe the same phenomenon. In social sciences and public health social inequities refer to the systematic lack of fairness or justice related to gender, ethnicity, geographical location and religion. These unequal social relations and structures of power operate to produce experiences of inequitable health outcomes, treatment and access to care. Health and social programs are often designed with the aim to address the lack of fairness and adjust for these systematic failures of systems or policies.)*

*Reference: The definition was adapted from Ingram R et al. Social Inequities and Mental Health: A Scoping Review. Vancouver: Study for Gender Inequities and Mental Health, 2013.

17 Local policies, practices, and laws considered during program design

How have local policies, practices, and laws (e.g., infrastructure development regulations, education requirements, etc.) been taken into consideration when designing the program?

18 How diversion of resources from other public health priorities are avoided

Please explain how the program avoids diverting resources away from other public health priorities? (e.g. local human resources involved in program implementation diverted from other programs or activities).

19 Program provides health technologies

Does your program include health technologies (health technologies include medical devices, medicines, and vaccines developed to solve a health problem and improve quality of lives)? (Yes/No)

20 Health technology(ies) are part of local standard treatment guidelines

Are the health technology(ies) which are part of your program part of local standard treatment guidelines? (Yes/No) If not, what was the local need for these technologies?

21 Health technologies are covered by local health insurance schemes

Does your program include health technologies that are covered by local health insurance schemes? (Yes/No) If not, what are the local needs for these technologies?

22 Program provides medicines listed on the National Essential Medicines List

Does your program include medicines that are listed on the National Essential Medicines List? (Yes/No) If not, what was the local need for these technologies?

23 Sustainability plan

If applicable, please describe how you have planned for sustainability of the implementation of your program (ex. Creating a transition plan from your company to the local government during the development of the program).

ADDITIONAL PROGRAM INFORMATION

24 Additional program information

Is there any additional information that you would like to add about your program that has not been collected in other sections of the form?

a Potential conflict of interest discussed with government entity

Have you discussed with governmental entity potential conflicts of interest between the social aims of your program and your business activities? (Yes/No) If yes, please provide more details and the name of the government entity.

25 Access Accelerated Initiative participant

Is this program part of the Access Accelerated Initiative? (Yes/No)

26 International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) membership

Is your company a member of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)? (Yes/No)

Program Indicators

INDICATOR DESCRIPTION

27 List of indicator data to be reported into Access Observatory database

For this program, activities, please select all inputs and impacts for which you plan to collect and report data into this database.

28 Data source

For this indicator, please select the data source(s) you will rely on.

29 Frequency of reporting

Indicate the frequency with which data for this indicator can be submitted to the Observatory.

30 Data collection

- Responsible party: For this indicator, please indicate the party/parties responsible for data collection.
- Data collection — Description: Please briefly describe the data source and collection procedure in detail.
- Data collection — Frequency: For this indicator, please indicate the frequency of data collection.

31 Data processing

- Responsible party: Please indicate all parties that conduct any processing of this data.
- Data processing— Description: Please briefly describe all processing procedures the data go through. Be explicit in describing the procedures, who enacts them, and the frequency of processing.
- Data processing — Frequency: What is the frequency with which this data is processed?

32 Data validation

Description: Describe the process (if any) your company uses to validate the quality of the data sent from the local team.

33 Challenges in data collection and steps to address challenges

Please indicate any challenges that you have in collecting data for this indicator and what you are doing to address those challenges.